Abemaciclib as initial therapy for advanced breast cancer: MONARCH 3 updated results in prognostic subgroups
Abstract In MONARCH 3, continuous dosing of abemaciclib with an aromatase inhibitor (AI) conferred significant clinical benefit to postmenopausal women with HR+, HER2− advanced breast cancer. We report data for clinically prognostic subgroups: liver metastases, progesterone receptor status, tumor gr...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Publishing Group
2021-06-01
|
| Series: | npj Breast Cancer |
| Online Access: | https://doi.org/10.1038/s41523-021-00289-7 |